Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Asthom** is a Taj Pharma fixed-dose oral bronchodilator product containing **salbutamol sulfate** and **anhydrous theophylline**. Standard Asthom tablets contain salbutamol 2 mg plus theophylline 100 mg; Asthom syrup contains salbutamol 1 mg plus theophylline 50 mg per 5 mL. Salbutamol is a short-acting beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, while theophylline is a methylxanthine bronchodilator with phosphodiesterase-inhibitory and adenosine-receptor-antagonist activity. Taj Pharma identifies Asthom for asthma, particularly where bronchodilation with more than one drug class is required. ([tajpharma.com](https://tajpharma.com/asthom-taj-products.htm))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Asthom.